… -agent chemotherapy in patients who acquired resistance to erlotinib/gefitinib and progressed
on afatinib after initial benefit. LUX-Lung 5 is the first prospective trial to demonstrate the …

… lung adenocarcinoma who had received at least one platinum-based chemotherapy regimen,
and at least 12 weeks of previous erlotinib or gefitinib … sensitive to erlotinib and gefitinib. …

… to that of the current LUX-Lung 4 trial with prior failure of erlotinib and/or gefitinib and an … ,
neratinib, and the combination of cetuximab plus erlotinib showed low ORR ranging from 0% to …

… LUX-Lung 8 compared afatinib (an irreversible ErbB family blocker) with erlotinib (a … ),
as second-line treatment for patients with advanced squamous cell carcinoma of the lung. …

… Five hundred and eighty-five patients with lung adenocarcinoma (stage IIIb/IV), who had
progressed after chemotherapy (1–2 lines) and at least 12 weeks of erlotinib or gefitinib, were …

… In the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (…
(OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing …

… It is known that 50%‒60% of patients treated with erlotinib or gefitinib develop T790M-…
compared gefitinib with erlotinib and found no difference in efficacy and safety [26], LUX-Lung 7 is …

… to reversible TKIs such as gefitinib and erlotinib develops in all … M, that renders gefitinib and
erlotinib ineffective inhibitors of EGFR/… to gefitinib and erlotinib in T790 M models in vivo [14]. …

… in efficacy between gefitinib, erlotinib, or … erlotinib and gefitinib (NCT01955421); a phase
3 trial comparing dacomitinib (a second-generation tyrosine kinase inhibitor) versus gefitinib (…

… Erlotinib and gefitinib were the initial TKIs to be approved for lung cancer and showed improved
… Afatinib has been tested as first-line treatment of advanced NSCLC in the LUX-Lung trial …